Agios Pharm Stock Filter Stocks by Fundamentals
| AGIO Stock | USD 58.66 0.44 0.74% |
Agios Pharm fundamentals help investors to digest information that contributes to Agios Pharm's financial success or failures. It also enables traders to predict the movement of Agios Stock. The fundamental analysis module provides a way to measure Agios Pharm's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Agios Pharm stock.
Agios | Cash and Equivalents |
Did you try this?
Run My Watchlist Analysis Now
My Watchlist AnalysisAnalyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like |
| All Next | Launch Module |
Agios Pharm ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Agios Pharm's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Agios Pharm's managers, analysts, and investors.Environmental | Governance | Social |
Agios Fundamentals
| Return On Equity | 0.54 | ||||
| Return On Asset | -0.18 | ||||
| Profit Margin | 20.51 % | ||||
| Operating Margin | (11.47) % | ||||
| Current Valuation | 2.4 B | ||||
| Shares Outstanding | 57.03 M | ||||
| Shares Owned By Insiders | 1.50 % | ||||
| Shares Owned By Institutions | 98.50 % | ||||
| Number Of Shares Shorted | 4.55 M | ||||
| Price To Earning | 1.26 X | ||||
| Price To Book | 2.06 X | ||||
| Price To Sales | 101.77 X | ||||
| Revenue | 26.82 M | ||||
| Gross Profit | 12.54 M | ||||
| EBITDA | (384.86 M) | ||||
| Net Income | (352.09 M) | ||||
| Cash And Equivalents | 819.31 M | ||||
| Cash Per Share | 14.95 X | ||||
| Total Debt | 72 M | ||||
| Debt To Equity | 0.08 % | ||||
| Current Ratio | 17.98 X | ||||
| Book Value Per Share | 28.53 X | ||||
| Cash Flow From Operations | (296.06 M) | ||||
| Short Ratio | 6.65 X | ||||
| Earnings Per Share | 11.66 X | ||||
| Target Price | 53.88 | ||||
| Number Of Employees | 383 | ||||
| Beta | 0.75 | ||||
| Market Capitalization | 3.35 B | ||||
| Total Asset | 937.12 M | ||||
| Retained Earnings | (822.65 M) | ||||
| Working Capital | 765.88 M | ||||
| Current Asset | 337.33 M | ||||
| Current Liabilities | 52.89 M | ||||
| Net Asset | 937.12 M |
About Agios Pharm Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Agios Pharm's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Agios Pharm using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Agios Pharm based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with Agios Pharm
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Agios Pharm position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Agios Pharm will appreciate offsetting losses from the drop in the long position's value.Moving together with Agios Stock
Moving against Agios Stock
| 0.8 | PFE | Pfizer Inc Aggressive Push | PairCorr |
| 0.73 | JNJ | Johnson Johnson Fiscal Year End 28th of January 2025 | PairCorr |
| 0.73 | LLY | Eli Lilly Sell-off Trend | PairCorr |
| 0.73 | TAK | Takeda Pharmaceutical | PairCorr |
| 0.71 | RDY | Dr Reddys Laboratories | PairCorr |
The ability to find closely correlated positions to Agios Pharm could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Agios Pharm when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Agios Pharm - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Agios Pharm to buy it.
The correlation of Agios Pharm is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Agios Pharm moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Agios Pharm moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Agios Pharm can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Agios Pharm Piotroski F Score and Agios Pharm Altman Z Score analysis. To learn how to invest in Agios Stock, please use our How to Invest in Agios Pharm guide.You can also try the Portfolio Volatility module to check portfolio volatility and analyze historical return density to properly model market risk.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Agios Pharm. If investors know Agios will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Agios Pharm listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share 11.66 | Revenue Per Share 0.582 | Quarterly Revenue Growth 0.212 | Return On Assets (0.18) | Return On Equity 0.5366 |
The market value of Agios Pharm is measured differently than its book value, which is the value of Agios that is recorded on the company's balance sheet. Investors also form their own opinion of Agios Pharm's value that differs from its market value or its book value, called intrinsic value, which is Agios Pharm's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Agios Pharm's market value can be influenced by many factors that don't directly affect Agios Pharm's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Agios Pharm's value and its price as these two are different measures arrived at by different means. Investors typically determine if Agios Pharm is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Agios Pharm's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.